Scientists at the University of York, in conjunction with the York Clinical Research Facility, will start the first phase of trials looking into a new way to prevent HIV transmission.
18 February 2015 | HIV / AIDS News From Medical News Today
The failure of the VOICE trial of H.I.V.-prevention methods in Africa — and the elaborate deceptions employed by the women in it — have opened an ethical debate about how to run such studies in poor countries and have already changed the design of some that are now underway.
05 February 2015 | New York Times
HIV/Aids researchers are anticipating positive results from a large-scale trial assessing the efficacy of a vaginal microbicide gel in preventing HIV infection in women.
21 January 2015 | AllAfrica.com
Dr. Deborah Anderson from Boston University School of Medicine and her colleagues are challenging dogma about the transmission of HIV. Most research has focused on infection by free viral particles, while this group proposes that HIV is also transmitted by infected cells. While inside cells, HIV is protected from antibodies and other antiviral factors. Anderson chides fellow researchers for not using cell-associated HIV in their transmission models: "The failure of several recent vaccine and microbicide clinical trials to prevent HIV transmission may be due in part to this oversight." . The Journal of Infectious Diseases (JID) has devoted their December supplement to this important and understudied topic.
23 December 2014 | Medical News Today
Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."
26 November 2014 | Huffington Post
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
Most microbicides work by targeting the virus itself, attempting to break it down or blocking its ability to infect a cell. However, the heightened infectiousness of HIV in the presence of semen appears to over-power any anti-viral effects the microbicides possess. The one exception to this finding is a different type of microbicide that acts on the host cells' receptors, stopping the virus from latching on from within. In the current study, this microbicide, [containing the drug called] called Maraviroc, was equally effective in preventing infection both with and without the presence of semen.
13 November 2014 | MedicalXpress
A recent journal article reviewed the challenges and successes in developing rectal microbicides, including the state of the current field, which we summarize here.
11 November 2014 | BETA blog
At this first international meeting to bring researchers from all biomedical HIV prevention approaches together under one roof, neither the time and disappointments leading up to this point, or the uncertainty of how much more time lies ahead, did anything to dampen a sense of optimism and ambition that AVAC director Mitchell Warren sums up as “momentum.”
05 November 2014 | Science Speaks
University of Washington researchers have created a discreet, quick-dissolving tampon out of silk-line fibers to protect women from HIV. The researchers would ideally like to develop a tampon to protect against HIV, herpes, and pregnancy — an all-in-one shield against the risks of sex. This could prove especially useful in developing countries, where women may not have easy access to other kinds of birth control.
04 November 2014 | Healthline News